IRLAB Therapeutics AB Sustainability Reports

IRLAB Therapeutics AB is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders.

Sector: Manufacturing

Country: Sweden

Exchange: Nasdaq Stockholm

LEI: 549300JAT34LHEI0DH60

FIGI: BBG00G3F2CD4

10 reports from 2017 to 2025

• IRLAB Therapeutics AB 2025 Annual Report
• IRLAB Therapeutics AB 2024 Annual Report
• IRLAB Therapeutics AB 2023 Annual Report
• IRLAB Therapeutics AB 2022 Annual Report
• IRLAB Therapeutics AB 2021 Annual Report